Brief: Active Biotech says receives European patent for tasquinimod

Active Biotech AB publ

09/01/2017 12:00

Jan 9 (Reuters) - Active Biotech AB  ACTI.ST  
    * Says the European Patent Office grants patent for 
tasquinimod for treatment of multiple myeloma 
    * Says the patent will be granted on February 
1, 2017 and has a duration lasting until 2035 
 
Source text for Eikon:  ID:nGNE38dvQf  
Further company coverage:  ACTI.ST  
 
 (Stockholm Newsroom) 
 ((stockholm.newsroom@thomsonreuters.com; +46 (0)8-700 10 10;))